The drug definition and principle of action of Mavakatai/Mefanto

Mavacamten is a new oral drug mainly used to treat hypertrophic cardiomyopathy (HCM). Hypertrophic cardiomyopathy is a heart disease characterized by abnormal thickening of the heart muscle, particularly the left ventricular wall. This thickening can lead to heart dysfunction and increase the risk of heart failure and other serious cardiovascular events. Mavaceta is a selective troponin modulator designed to improve the clinical symptoms of patients with hypertrophic cardiomyopathy by regulating myocardial contraction.

In the treatment of hypertrophic cardiomyopathy, the mechanism of action of Mavaceta is focused on regulating calcium ion handling and troponin function in cardiomyocytes. Troponin is a key protein in cardiac muscle contraction, and its role is to mediate the contraction and relaxation of cardiomyocytes. In hypertrophic cardiomyopathy, the contractility of the heart muscle is abnormally increased. This abnormal contractility leads to thickening of the heart muscle and restricted blood flow. By selectively inhibiting the excessive activation of troponin, Mavakatai reduces the tension of the myocardium, thereby improving the diastolic function of the heart, relieving the patient's symptoms and reducing the burden on the heart.

The pharmacological mechanism of Mavaceta can effectively restore the normal function of the heart by reducing unnecessary muscle contraction. It is different from traditional drugs for the treatment of hypertrophic cardiomyopathy, such as β-blockers and calcium channel blockers. Mavaceta directly acts on the molecular mechanism in myocardial cells to reduce excessive contraction of the heart and improve diastolic function of the heart, thereby reducing symptoms caused by cardiac hypertrophy in patients with hypertrophic cardiomyopathy, such as shortness of breath, fatigue and decreased exercise tolerance.

In addition, Mavaceta is designed for oral administration, making it easier for patients to use it long-term and maintain efficacy. Its treatment method is individualized management, and the dosage is adjusted according to the patient's symptoms and condition to achieve good therapeutic effects. Patients need to regularly monitor their cardiac function during treatment to ensure that the medicine can work safely and effectively.

Keyword tags:

Mavacatel, Maivantol, hypertrophic cardiomyopathy, drug action principle, troponin modulator, cardiovascular treatment, oral drugs, myocardial contraction, clinical treatment

Reference materials:https://www.ema.europa.eu/en/documents/product-information/camzyos-epar-product-information_en.pdf